Please login to the form below

Not currently logged in
Email:
Password:

Brilique

This page shows the latest Brilique news and features for those working in and with pharma, biotech and healthcare.

NICE backs expanded use of Brilique in final guidance

NICE backs expanded use of Brilique in final guidance

AZ’s maintenance therapy recommended for long-term use, post-heart attack. NICE has recommended AstraZeneca's Brilique (ticagrelor) as a long-term treatment for patients who have had a heart ... Brilique brought in sales of $395m in the first half of

Latest news

More from news
Approximately 5 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • The evolution of IQWiG in Germany’s drug pricing policy The evolution of IQWiG in Germany’s drug pricing policy

    This includes MSD's hepatitis C drug Victrelis and AstraZeneca's blood clotting drug Brilique. ... With Brilique, IQWiG wanted to split the patient population into four different sub-populations, from which only one received a label of additional benefit.

  • Drug pricing in Ireland Drug pricing in Ireland

    It said that up to 10 new medicines that had proved cost effective through HTA – including Brilique, Gileyna, Sycrest, Incivo and Victrelis – were still not being reimbursed.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • AZ names Brilique lead in Spain AZ names Brilique lead in Spain

    In this role Gribble will be responsible for the company's marketing of Brilique (ticagrelor) for acute coronary syndrome, including management, development and market access activities, and he will also be ... Gribble has been with AstraZeneca in Spain

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics